Intravenous anesthetics are known to cause amnesia, but the underlying molecular mechanisms remain elusive. To identify a possible molecular mechanism, we recently turned our attention to a key intracellular signaling pathway organized by a family of mitogen-activated protein kinases (MAPKs). As a prominent synapse-to-nucleus superhighway, MAPKs couple surface glutamate receptors to nuclear transcriptional events essential for the development and/or maintenance of different forms of synaptic plasticity (long-term potentiation and long-term depression) and memory formation. To define the role of MAPK-dependent transcription in the amnesic property of anesthetics, we conducted a series of studies to examine the effect of a prototype intravenous anesthetic propofol on the MAPK response to N-methyl-Daspartate receptor (NMDAR) stimulation in hippocampal neurons. Our results suggest that propofol possesses the ability to inhibit NMDAR-mediated activation of a classic subclass of MAPKs, extracellular signal-regulated protein kinase 1/2 (ERK1/2). Concurrent inhibition of transcriptional activity also occurs as a result of inhibited responses of ERK1/2 to NMDA. These findings provide first evidence for an inhibitory modulation of the NMDAR-MAPK pathway by an intravenous anesthetic and introduce a new avenue to elucidate a transcription-dependent mechanism processing the amnesic effect of anesthetics.
Introduction
Mitogen-activated protein kinases (MAPKs), a large family of cytosolic and nuclear serine/threonine kinases [1] , have been implicated in the regulation of a variety of cellular and synaptic activities in proliferative cells as well as matured neurons. In particular, MAPKs form central signaling pathways processing inducible gene expression in response to various forms of extracellular and intracellular inputs. Activation of glutamate receptors, such as N-methyl-D-aspartate receptor (NMDAR) subtype, results in a robust activation of the MAPK pathway and thus gene expression in hippocampal CA1 neurons. This stimulustranscription coupling has been demonstrated to be critical molecular steps toward the development and/or maintenance of two forms of synaptic plasticity: long-term potentiation (LTP) and long-term depression (LTD). It is generally accepted that the NMDAR-MAPK-LTP/LTD cascade constitutes an efficient transcription-dependent apparatus controlling the memory formation.
Intravenous anesthetics are known to produce amnesia, although potential molecular mechanism(s) underlying this adverse effect have long been puzzling. It has been noted that anesthetics can produce amnesia that long outlasts the duration of anesthesia. This suggests that there exists a relatively long-lasting biochemical process mediating the amnesic action. In searching for this responsible biochemical process, we recently hypothesized that anesthetic drugs may affect a transcription-dependent memory formation that results in amnesia. To experimentally explore this possibility, we conducted a series of pharmacological and molecular experiments in cultured rat hippocampal CA1 neurons. We found that the intravenous anesthetic propofol displayed the ability to potently suppress the NMDAR function and NMDAR-mediated MAPK activation and gene expression. This provides evidence for an inhibitory influence of anesthetics over the sequential NMDAR-MAPK-transcription cascade and suggests a novel avenue to uncover molecular mechanisms for the amnesic effect of anesthetics.
2 The Ras-MAPK pathway and its role in transcription-dependent synaptic plasticity related to the memory formation MAPKs are a superfamily of protein kinases that are densely expressed in postmitotic neurons of adult mammalian brain. As important kinases in several key signaling cascades, MAPKs are actively involved in the regulation of various cellular and synaptic activities [1] . Activation of MAPKs involves a consecutive and sequential phosphorylation of four levels of signaling proteins: small GTPases (Ras and Rac proto-oncogenes), MAPK kinase kinases (Raf or MEKKs), MAPK kinases (MEKs), and MAPKs. In the case of extracellular signal-regulated protein kinase 1/2 (ERK1/2) subfamily of MAPKs, a prototype of MAPKs, they are activated via phosphorylation on Thr202 and Tyr204 through the upstream Ras-Raf-MEK1/2 pathway. Once activated, ERK1/2 translocate from the cytosol to the nucleus to activate specific transcription factors, leading to inducible gene expression [2] . L-glutamate is among neurotransmitters that readily activate ERK1/2 in neurons (reviewed in Ref. 3) . All glutamate receptors surveyed so far, including all ionotropic and metabotropic glutamate receptor subtypes, have been demonstrated to positively regulate ERK1/2 phosphorylation [3] . The NMDAR is the most thoroughly characterized subtype in this event. In various brain regions, NMDARs consistently show the ability to upregulate ERK1/2 phosphorylation. The Ca 2+ -permeable NMDAR is believed to activate ERK1/2 via at least two Ca 2+ -dependent routes [3] . First, Ca 2+ signals derived from the Ca 2+ influx through
NMDARs activate several Ca 2+ -sensitive protein kinases to increase ERK1/2 phosphorylation [4] . Ca 2+ /calmodulindependent protein kinases (CaMKs) and phosphatidylinositol (phosphoinositide) 3-kinases (PI3-kinases) are two important elements for forming a pathway to link NMDARs to ERK1/2. The second signaling route linking NMDARs to ERK1/2 involves a direct interaction between the NMDAR NR2B subunit and Ras-guanine nucleotide releasing factors (RasGRFs), a neuron-specific activator of Ras. The direct binding of NR2B and RasGRFs creates a submembranous microdomain ensuring rapid transmission of Ca 2+ signals to the Ras-ERK1/2 cascade [5] . A noticeable role of active ERK1/2 is its strong regulation of gene expression. As an information superhighway between the surface receptor and the nucleus, ERK1/2 effectively link environmental inputs to genomic responses. In the cytoplasm, this action involves a rapid phosphorylation of ERK1/2 followed by dynamic translocation of phospho-ERK1/2 to the nucleus. In the nucleus, ERK1/2 activate specific sets of transcription factors including Elk-1 and cAMP response element-binding protein (CREB) by increasing their phosphorylation at Ser383 (Elk-1) and Ser133 (CREB). Active transcription factors in turn bind to specific promoter sites to facilitate target gene expression. A large number of genes are able to respond to this ERK1/2-dependent signaling pathway following NMDAR stimulation [6, 7] . Altered expression of genes, especially those perisynaptic proteins, are thought to be dynamic adaptive changes important for synaptic plasticity related to long-lasting changes in efficacy and strength of synapses.
A significant contribution of ERK1/2 to synaptic plasticity and memory formation in the adult brain has been established in several behavioral and cellular studies [8, 9] .
This contribution is largely derived from the regulatory role of ERK1/2 in gene expression. Through regulating specific sets of transcriptional events, ERK1/2 modulate expression levels and thus functions of various key synaptic proteins. This process influences many forms of synaptic plasticity, including LTP and LTD, cellular models of learning and memory. In the hippocampal CA1 region, LTP can last for hours and requires de novo transcription and protein synthesis [10] . Similarly, several forms of learning behaviors are mRNA-and protein synthesis-dependent [11] . In the light of NMDAR-dependent forms of LTP, it has been shown that NMDAR-gated Ca 2+ influx activates the ERK1/2 pathway, which in turn increases the Elk-1-and CREB-dependent transcription of a family of genes essential for the induction and/or maintenance of LTP [8, 9] .
Amnesic effect of anesthetic drugs and a potential transcription-dependent mechanism involving the ERK1/2 pathway
One of adverse consequences after clinical use of anesthetic drugs is the occurrence of amnesia or the inability to remember events. This type of loss of memory is particularly sensitive to general anesthetics because amnesia occurs at concentrations well below those that cause sedation and immobility. Commonly used inhaled and intravenous anesthetics all cause amnesia usually at concentrations several fold lower than those required for immobility. Noticeably, such amnesia can last much longer than the duration of anesthesia, indicating an involvement of a relatively long-lasting biochemical process in this event. While detailed molecular mechanisms underlying the amnesic effect of anesthetics are unclear, the transcription-dependent learning and memory mechanism has drawn attention. A tempting scenario is that anesthetic drugs may suppress NMDAR-and ERK1/2-dependent LTP, which in turn results in an impaired memory. To test this possibility, a complete set of in vitro experiments has recently been conducted in this laboratory [12] and the results from these experiments seem to support the involvement of NMDAR and ERK1/2 in amnesic effects of anesthetics. We have chosen propofol (2,6-diisopropylphenol), a highly effective intravenous anesthetic, as our prototype anesthetic agent for study. This drug is currently widely used for general anesthesia or for sedation with local anesthesia and in intensive care units. Like other intravenous anesthetics, propofol produces amnesia and its suppression of memory function can persist for several hours after propofol administration [13] . The amnesic effect of propofol has already been linked to its known inhibition of LTP at Schaffer collateral-commissural pathway to CA1 pyramidal cell synapses in the hippocampus [14] [15] [16] , although, at present, molecular mechanisms underlying the propofol inhibition of hippocampal LTP are poorly understood. To unravel possible molecular mechanisms for the propofol inhibition of LTP, we initiated an effort to test the effect of propofol on the ERK1/2 response to NMDAR inputs in cultured rat hippocampal CA1 neurons. We found that propofol consistently inhibited the NMDAR mediated activation of the ERK1/2 pathway. This for the first time reveals that propofol possesses the ability to inhibit the ERK1/2 response to NMDAR activation. Noticeably, the propofol effect was achieved at a low concentration range (1-10 mol/L) which is thus believed to be clinically relevant because propofol at blood concentrations (approximately 3.5-3.7 mol/L) produced 50% loss of memory [17, 18] . We then set out to elucidate how propofol suppresses the ERK1/2 response. We speculated that propofol may achieve its effect by inhibiting NMDARs or any component of a signaling pathway linking NMDAR to Ras-ERK1/2. NMDAR NR1 subunits undergo a tight phosphorylation at two distinct sites (Ser897 and Ser896) of their intracellular C-termini [19] . Such phosphorylation represents a major posttranslational modification of NMDAR function [20] . It is possible that propofol may affect NMDAR phosphorylation and thus function to modulate NMDAR-dependent ERK1/2 phosphorylation. To determine whether propofol affects NR1 phosphorylation, the effect of propofol on NR1 phosphorylation at Ser897 and Ser896 was tested in hippocampal neurons using a phospho-and site-specific antibody. It was found that propofol reduced Ser897 and Ser896 phosphorylation [21] , indicating the ability of propofol to regulate NR1 phosphorylation in an inhibitory fashion. To determine whether the reduced NR1 phosphorylation occurs in parallel with any change of NMDAR function, we examined the effect of propofol on NMDAR-mediated Ca 2+ influx under the same experimental conditions. We found that Ca 2+ rises in response to NMDA stimulation was reduced in neurons exposed to propofol. Thus, NMDAR function in terms of Ca 2+ influx was as sensitive as NMDAR phosphorylation in response to propofol application, although the direct causal relation between the two events was not defined in this study. Nevertheless, propofol was demonstrated to suppress NMDAR phosphorylation and NMDAR-mediated Ca 2+ entry simultaneously. Since NMDAR-regulated ERK1/2 phosphorylation is Ca 2+ -sensitive, the inhibitory effect of propofol on Ca 2+ responses to NMDA may at least in part account for the propofolinduced reduction of ERK1/2 responses to NMDA. As aforementioned, active ERK1/2 phosphorylate nuclear transcription factors and facilitate gene expression. We then attempted to determine whether the impaired ERK1/2 response to NMDA by propofol has any effect on inducible gene expression. We tested Elk-1 and CREB, two specific factors downstream to the ERK1/2 pathway [22] [23] [24] , for their responses to NMDA stimulation in the presence of propofol. In addition, an immediate early gene c-Fos was tested as a reporter of inducible gene expression downstream to Elk-1 and CREB to determine a final output of gene expression. We found that the NMDA-stimulated phosphorylation of Elk-1 and CREB and c-Fos expression were blocked by propofol. The same blocking effect was also seen when the ERK1/2 pathway was inhibited by a MEK selective inhibitor. Thus, propofol is capable of sup- 
Conclusions
An initial effort has been made to unravel a molecular mechanism responsible for the amnesic effect of intravenous anesthetics. Available data support a hypothesis that intravenous anesthetics such as propofol may produce amnesia through inhibiting NMDAR/ERK1/2-dependent LTP. As illustrated in Fig. 1 
